Verve Therapeutics, Inc. (VERV)
Automate Your Wheel Strategy on VERV
With Tiblio's Option Bot, you can configure your own wheel strategy including VERV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VERV
- Rev/Share 0.6862
- Book/Share 5.4506
- PB 0.8164
- Debt/Equity 0.145
- CurrentRatio 9.843
- ROIC -0.3643
- MktCap 396687240.0
- FreeCF/Share -1.6919
- PFCF -2.6989
- PE -2.1358
- Debt/Assets 0.1118
- DivYield 0
- ROE -0.3582
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | VERV | Cantor Fitzgerald | Neutral | Overweight | -- | -- | April 15, 2025 |
News
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Read More
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago.
Read More
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Published: April 16, 2025 by: Seeking Alpha
Sentiment: Positive
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Read More
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
Read More
Why Verve Therapeutics Is Skyrocketing Today
Published: April 15, 2025 by: The Motley Fool
Sentiment: Positive
Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.
Read More
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
Published: April 14, 2025 by: Benzinga
Sentiment: Positive
Verve Therapeutics Inc VERV on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood.
Read More
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C).
Read More
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025
Read More
About Verve Therapeutics, Inc. (VERV)
- IPO Date 2021-06-17
- Website https://www.vervetx.com
- Industry Biotechnology
- CEO Dr. Sekar Kathiresan M.D.
- Employees 274